{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:55:10Z","timestamp":1793494510433,"version":"4.5.0"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.msard.2026.107173","type":"journal-article","created":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T07:05:43Z","timestamp":1775027143000},"page":"107173","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Real-world cost of disease-modifying treatments administered by intravenous infusion in relapsing-remitting multiple sclerosis patients from Argentina"],"prefix":"10.1016","volume":"110","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5866-2419","authenticated-orcid":false,"given":"Berenice A.","family":"Silva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda B.","family":"Federico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciana","family":"L\u00e1zaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Casas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcos","family":"Burgos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Maniella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dar\u00edo","family":"Tavolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edgar","family":"Carnero Contentti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ver\u00f3nica","family":"Tkachuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Vrech","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Agustina","family":"Z\u00e1rate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan I","family":"Rojas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Alonso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Elgart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2026.107173_bib0001","unstructured":"AlfaBeta, 2022. Precios de medicamentos 2022 (Accessed diciembre 2022)."},{"key":"10.1016\/j.msard.2026.107173_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.103751","article-title":"Decision making process in multiple sclerosis: an Argentine pilot study","volume":"61","author":"Alonso","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2026.107173_bib0002","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.104935","article-title":"Evaluation of the use of high-efficacy treatments (HETs) in patients with relapsing-remitting multiple sclerosis in Argentina","volume":"79","author":"Alonso","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"1","key":"10.1016\/j.msard.2026.107173_bib0004","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1080\/13696998.2023.2194185","article-title":"Real-world cost of care and site of care in patients with multiple sclerosis initiating infused disease-modifying therapies","volume":"26","author":"Alvarez","year":"2023","journal-title":"J. Med. Econ."},{"key":"10.1016\/j.msard.2026.107173_bib0005","unstructured":"ANMAT, 2022. Vademecun ANMAT (Accessed diciembre 2022 2022)."},{"key":"10.1016\/j.msard.2026.107173_bib0006","series-title":"Ministerio De Hacienda y Finanzas P\u00fablicas","article-title":"Informes de cadenas de valor. Salud, farmacia y equipamiento m\u00e9dico","author":"Argentina","year":"2016"},{"key":"10.1016\/j.msard.2026.107173_bib0007","unstructured":"Argentina., B.C., 2022. Tipo de cambio por fecha. (Accessed 16-12-2022."},{"key":"10.1016\/j.msard.2026.107173_bib0008","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.msard.2016.07.007","article-title":"Increasing prevalence of multiple sclerosis in Buenos Aires, Argentina","volume":"9","author":"Cristiano","year":"2016","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2026.107173_bib30","unstructured":"European Medicines Agency. Lemtrada: EPAR - Product Information. 2023a. [cited 2023 Sep 17]. Available from: https:\/\/www.ema.europa.eu\/es\/documents\/product-information\/lemtrada-epar-product-information_es.pdf."},{"key":"10.1016\/j.msard.2026.107173_bib31","unstructured":"European Medicines Agency. Tysabri: EPAR - Product Information. 2023b. [cited 2023 Sep 17]. Available from: https:\/\/www.ema.europa.eu\/es\/documents\/product-information\/tysabri-epar-product-information_es.pdf."},{"key":"10.1016\/j.msard.2026.107173_bib32","unstructured":"European Medicines Agency. Ocrevus: EPAR - Product Information. 2023c. [cited 2023 Sep 17]. Available from: https:\/\/www.ema.europa.eu\/es\/documents\/product-information\/ocrevus-epar-product-information_es.pdf."},{"issue":"4","key":"10.1016\/j.msard.2026.107173_bib0012","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s41669-021-00282-7","article-title":"A model-based economic evaluation of Cladribine versus Alemtuzumab, Ocrelizumab and Natalizumab for the treatment of relapsing-remitting multiple sclerosis with high disease activity in Chile","volume":"5","author":"Espinoza","year":"2021","journal-title":"Pharmacoecon. Open."},{"key":"10.1016\/j.msard.2026.107173_bib0013","doi-asserted-by":"crossref","unstructured":"Hidalgo-Vega, \u00c1., 2020. El valor del medicamento desde una perspectiva social en Argentina y en pa\u00edses de su entorno (Accessed septiembre 2024 2024).","DOI":"10.37666\/L10-2020"},{"key":"10.1016\/j.msard.2026.107173_bib0015","doi-asserted-by":"crossref","DOI":"10.1177\/17562864211019574","article-title":"Long-term disability trajectories in relapsing multiple sclerosis patients treated with early intensive or escalation treatment strategies","volume":"14","author":"Iaffaldano","year":"2021","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.msard.2026.107173_bib0016","unstructured":"INDEC, 2023. Instituto Nacional de Estad\u00edstica y Censos de la Rep\u00fablica de Argentina. (Accessed septiembre 2024."},{"issue":"1","key":"10.1016\/j.msard.2026.107173_bib0017","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0208837","article-title":"Burden and cost of multiple sclerosis in Brazil","volume":"14","author":"Kobelt","year":"2019","journal-title":"PLoS. One"},{"issue":"4","key":"10.1016\/j.msard.2026.107173_bib0018","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s13760-013-0200-z","article-title":"Cost of care according to disease-modifying therapy in Mexicans with relapsing-remitting multiple sclerosis","volume":"113","author":"Macias-Islas","year":"2013","journal-title":"Acta Neurol. Belg."},{"issue":"6","key":"10.1016\/j.msard.2026.107173_bib0019","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0199446","article-title":"The long-term costs for treating multiple sclerosis in a 16-year retrospective cohort study in Brazil","volume":"13","author":"Maia Diniz","year":"2018","journal-title":"PLoS. One"},{"key":"10.1016\/j.msard.2026.107173_bib0025","unstructured":"Ministerio de Desarrollo Productivo. Direcci\u00f3n Nacional de Estudios para la Producci\u00f3n. Salario promedio por departamento\/partido y clae2, total. 2022 [cited 2023 Feb 23]. Available from: https:\/\/datos.gob.ar\/ca\/dataset\/produccion-salarios-por-departamentopartido-sector-actividad\/archivo\/produccion_d51dc195-d5ec-41f5-9186-091f12b264a7."},{"key":"10.1016\/j.msard.2026.107173_bib0020","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.vhri.2017.12.001","article-title":"Health care cost for multiple sclerosis: the case of a Health insurer in Colombia","volume":"17","author":"Munoz-Galindo","year":"2018","journal-title":"Value Health Reg. Issues."},{"issue":"8","key":"10.1016\/j.msard.2026.107173_bib0021","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1080\/13696998.2020.1761821","article-title":"Real-world cost of treatment for multiple sclerosis patients initiating and receiving infused disease-modifying therapies per recommended label in the United States","volume":"23","author":"Nicholas","year":"2020","journal-title":"J. Med. Econ."},{"issue":"1","key":"10.1016\/j.msard.2026.107173_bib0022","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1007\/s12325-020-01570-0","article-title":"Annual cost burden by level of relapse severity in patients with multiple sclerosis","volume":"38","author":"Nicholas","year":"2021","journal-title":"Adv. Ther."},{"issue":"4","key":"10.1016\/j.msard.2026.107173_bib0023","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1212\/WNL.0b013e3182270402","article-title":"Cost-effectiveness of disease-modifying therapy for multiple sclerosis: a population-based study","volume":"77","author":"Noyes","year":"2011","journal-title":"Neurology."},{"issue":"1","key":"10.1016\/j.msard.2026.107173_bib0024","first-page":"1","article-title":"The myths that drive therapeutic inertia in multiple sclerosis: a cost-effectiveness analysis of high-efficacy drugs in Brazil","volume":"82","author":"Pipek","year":"2024","journal-title":"Arq. Neuropsiquiatr."},{"issue":"2","key":"10.1016\/j.msard.2026.107173_bib0026","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1056\/NEJMra1401483","article-title":"Multiple sclerosis","volume":"378","author":"Reich","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2026.107173_bib0027","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.msard.2019.05.004","article-title":"The Argentinean multiple sclerosis registry (RelevarEM): methodological aspects and directions","volume":"32","author":"Rojas","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"2","key":"10.1016\/j.msard.2026.107173_bib0028","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol."},{"issue":"5","key":"10.1016\/j.msard.2026.107173_bib0029","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1590\/0004-282X20140016","article-title":"ENCOMS: argentinian survey in cost of illness and unmet needs in multiple sclerosis","volume":"72","author":"Ysrraelit","year":"2014","journal-title":"Arq. Neuropsiquiatr."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034826002099?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034826002099?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T15:23:19Z","timestamp":1780327399000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034826002099"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":28,"alternative-id":["S2211034826002099"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2026.107173","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world cost of disease-modifying treatments administered by intravenous infusion in relapsing-remitting multiple sclerosis patients from Argentina","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2026.107173","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107173"}}